NCT04753203View on ClinicalTrials.gov

Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

February 28, 2021

Primary Completion Date

February 28, 2024

Study Completion Date

February 28, 2025

Conditions
Metastatic Colorectal CancerPIK3CA Gene Mutation
Interventions
DRUG

Alpelisib plus Capecitabine combination

Adding Alpelisib to Capecitabine as a salvage regimen in mCRC with PIK3CA mutation

Trial Locations (1)

02841

Korea University Anam Hospital, Seoul

All Listed Sponsors
lead

Korean Cancer Study Group

OTHER